159 related articles for article (PubMed ID: 24034390)
1. Clinical remission of Merkel cell carcinoma after treatment with imatinib.
Loader DE; Feldmann R; Baumgartner M; Breier F; Schrama D; Becker JC; Steiner A
J Am Acad Dermatol; 2013 Oct; 69(4):e181-3. PubMed ID: 24034390
[No Abstract] [Full Text] [Related]
2. KIT mutations in a series of melanomas and their impact on treatment with imatinib.
Botella-Estrada R; Soriano V; Rubio L; Nagore E
Actas Dermosifiliogr; 2012 Nov; 103(9):838-40. PubMed ID: 22795573
[No Abstract] [Full Text] [Related]
3. Treatment of a multicentric Merkel cell carcinoma using imatinib.
Peuvrel L; Quereux G; Brocard A; Renaut JJ; Dréno B
Eur J Dermatol; 2011; 21(6):1009-10. PubMed ID: 21926041
[No Abstract] [Full Text] [Related]
4. [Merkel cell carcinoma: a rare tumor entity in an unusually young patient].
Rothe JH; Denecke T; Röttgen R
Rofo; 2009 Mar; 181(3):270-2. PubMed ID: 19229796
[No Abstract] [Full Text] [Related]
5. Overview of Merkel cell carcinoma and recent advances in research.
Smith K; Skelton H
Int J Dermatol; 2003 Sep; 42(9):749-51. PubMed ID: 12956696
[No Abstract] [Full Text] [Related]
6. Platelet-derived growth factor receptor alpha mutational status and immunohistochemical expression in Merkel cell carcinoma: implications for treatment with imatinib mesylate.
Swick BL; Ravdel L; Fitzpatrick JE; Robinson WA
J Cutan Pathol; 2008 Feb; 35(2):197-202. PubMed ID: 18190445
[TBL] [Abstract][Full Text] [Related]
7. Merkel cell carcinoma: an unusual indication for isolated limb perfusion.
Ponte P; Moniz JV; Farricha V; Weinholtz JB
Dermatol Online J; 2008 Jul; 14(7):6. PubMed ID: 18718190
[TBL] [Abstract][Full Text] [Related]
8. Merkel cell carcinoma: evaluation of KIT (CD117) expression and failure to demonstrate activating mutations in the C-KIT proto-oncogene - implications for treatment with imatinib mesylate.
Swick BL; Ravdel L; Fitzpatrick JE; Robinson WA
J Cutan Pathol; 2007 Apr; 34(4):324-9. PubMed ID: 17381803
[TBL] [Abstract][Full Text] [Related]
9. Dermatofibrosarcoma protuberans: a partial response to imatinib therapy.
Mehrany K; Swanson NA; Heinrich MC; Weenig RH; Lee KK; White CR; Devere TS
Dermatol Surg; 2006 Mar; 32(3):456-9. PubMed ID: 16640697
[No Abstract] [Full Text] [Related]
10. Imatinib mesylate in the treatment of a large unresectable dermatofibrosarcoma protuberans: a case study.
Savoia P; Ortoncelli M; Quaglino P; Bernengo MG
Dermatol Surg; 2006 Aug; 32(8):1097-102. PubMed ID: 16918576
[No Abstract] [Full Text] [Related]
11. A phase II trial of imatinib mesylate in merkel cell carcinoma (neuroendocrine carcinoma of the skin): A Southwest Oncology Group study (S0331).
Samlowski WE; Moon J; Tuthill RJ; Heinrich MC; Balzer-Haas NS; Merl SA; DeConti RC; Thompson JA; Witter MT; Flaherty LE; Sondak VK
Am J Clin Oncol; 2010 Oct; 33(5):495-9. PubMed ID: 20019577
[TBL] [Abstract][Full Text] [Related]
12. Response to a novel multitargeted tyrosine kinase inhibitor pazopanib in metastatic Merkel cell carcinoma.
Davids MS; Charlton A; Ng SS; Chong ML; Laubscher K; Dar M; Hodge J; Soong R; Goh BC
J Clin Oncol; 2009 Sep; 27(26):e97-100. PubMed ID: 19564526
[No Abstract] [Full Text] [Related]
13. Imatinib mesylate for melanoma: will a new target be revealed?
Grossman D
J Invest Dermatol; 2004 Dec; 123(6):xi-xiii. PubMed ID: 15610499
[No Abstract] [Full Text] [Related]
14. Apparent response of cutaneous Merkel cell tumor to topical imiquimod.
Scott DR
Cutis; 2006 Feb; 77(2):109-10; author reply 110. PubMed ID: 16570674
[No Abstract] [Full Text] [Related]
15. Successful treatment of unresectable dermatofibrosarcoma protuberans on finger with imatinib mesylate and Mohs microsurgery.
Jeon IK; Kim JH; Kim SE; Kim SC; Roh MR
J Dermatol; 2013 Apr; 40(4):288-9. PubMed ID: 23293988
[No Abstract] [Full Text] [Related]
16. Subcutaneous metastasis of a GIST tumour unresponsive to Imatinib.
Jones AP; Allison K
J Plast Reconstr Aesthet Surg; 2011 Sep; 64(9):e250-1. PubMed ID: 21536512
[No Abstract] [Full Text] [Related]
17. A violaceous nodule on the knee. Merkel cell carcinoma (MCC).
Strahan JE; Fujita M
Arch Dermatol; 2009 Jun; 145(6):715-20. PubMed ID: 19528432
[No Abstract] [Full Text] [Related]
18. CNS and cutaneous involvement in patients with chronic myeloid leukemia treated with imatinib in hematologic complete remission: two case reports.
Abruzzese E; Cantonetti M; Morino L; Orlandi G; Tendas A; Del Principe MI; Masi M; Amadori S; Orlandi A; Anemona L; Campione E
J Clin Oncol; 2003 Nov; 21(22):4256-8. PubMed ID: 14615464
[No Abstract] [Full Text] [Related]
19. Inimitable Imatinib: the range of targeted tumours expands to include T-cell lymphoma.
Turner SD
Leukemia; 2013 Apr; 27(4):759. PubMed ID: 23575607
[No Abstract] [Full Text] [Related]
20. Imatinib-induced amelioration of neurologic deficits in a rare case of simultaneous association of missed multiple sclerosis and chronic myeloblastic leukemia.
Siroos B; Harirchian MH; Abolfazli R
Mult Scler; 2013 Aug; 19(9):1238-9. PubMed ID: 23339135
[No Abstract] [Full Text] [Related]
[Next] [New Search]
